Paratek Pharmaceuticals, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. (PRTK) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies addressing life-threatening infectious diseases, antimicrobial resistance, and other public health threats for civilian, government, and military use; its flagship product NUZYRA (omadacycline) comprises once-daily oral and intravenous formulations indicated for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in adults; SEYSARA (sarecycline), a narrow-spectrum once-daily oral therapy for moderate to severe acne vulgaris in patients aged 9 and older, rounds out its marketed antibiotic portfolio alongside investigational applications of NUZYRA under a BARDA Project BioShield contract for anthrax. Founded in 1996 and headquartered in Boston, Massachusetts, the company operates primarily in the United States with global rights to omadacycline except in Greater China, where it collaborates with Zai Lab (Shanghai) Co., Ltd., and targets specialists, primary care providers, and biodefense sectors. In May 2025, Paratek completed its acquisition of Optinose, Inc., adding XHANCE (fluticasone propionate), an exhalation delivery system for chronic rhinosinusitis without nasal polyps, to broaden its commercial offerings beyond antibiotics into ear, nose, and throat therapeutics and establish a multi-product platform for future expansions.
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026
Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform
Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025
Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025
Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities
Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease
Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024
Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia
Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
Novo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Paratek Pharmaceuticals, Inc. by Gurnet Point Capital
Investor Alert: Abbott Cooper PLLC Announces Investigation into Paratek Pharmaceuticals, Inc.; Urges Paratek Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates
Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million